What is the main purpose of this 8-K filing for Cardinal Health?

This 8-K filing primarily announces Cardinal Health's entry into a material definitive agreement, specifically a Stock Purchase Agreement to acquire Kinray, Inc. It provides key details about the transaction, including the purchase price, conditions for closing, and termination provisions.

How much is Cardinal Health paying for Kinray, Inc. and what are the key financial considerations?

Cardinal Health is acquiring Kinray, Inc. for a purchase price of approximately $1.3 billion. This price is subject to adjustments based on Kinray's working capital, indebtedness, and certain other expenses at the time of closing.

What are the main conditions that must be met before the acquisition can be completed?

The acquisition is subject to customary closing conditions. The most significant of these is the expiration or termination of any waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act. Other conditions include the accuracy of representations and warranties and material compliance with covenants by both parties.

Are there any penalties or fees associated with delays or termination of this agreement?

Yes, there are financial implications for delays and potential terminations. If the closing does not occur by January 1, 2011, Cardinal Health will pay Kinray an additional $200,000 for each day of delay. Cardinal Health may also have to pay a $65 million termination fee under specific circumstances, such as the commencement of a governmental proceeding to prohibit the transaction or if closing conditions are met but the transaction is not completed by August 17, 2011.

CAH 8-K: Material Agreements & Regulation FD

Summary

Cardinal Health Inc. (CAH) announced on November 17, 2010, a significant strategic move with the signing of a Stock Purchase Agreement to acquire Kinray, Inc. for approximately $1.3 billion. This acquisition is poised to make Kinray a wholly-owned subsidiary of Cardinal Health, indicating a substantial expansion of the company's operations and market presence. The agreement is subject to customary closing conditions, including regulatory approval under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act. The deal also includes provisions for potential financial adjustments based on working capital, indebtedness, and certain expenses, as well as a daily penalty if the closing is delayed beyond January 1, 2011. Investors should note the termination clauses and the potential $65 million termination fee under specific circumstances, signaling a carefully structured transaction with defined risks and responsibilities for both parties.

Key Highlights

1Cardinal Health entered into a Stock Purchase Agreement to acquire Kinray, Inc. for approximately $1.3 billion.
2The acquisition is expected to make Kinray a wholly-owned subsidiary of Cardinal Health.
3Closing of the transaction is contingent upon customary conditions, including HSR Act antitrust approval.
4The purchase price is subject to adjustments for working capital, indebtedness, and certain expenses.
5A daily penalty of $200,000 will be paid by Cardinal Health if the closing is delayed beyond January 1, 2011.
6The agreement includes termination rights for both parties, with a potential $65 million termination fee payable by Cardinal Health under specific scenarios.
7This filing also incorporates by reference a press release and Q&A document providing further details on the transaction.

CARDINAL HEALTH INC 8-K Report, Material Agreement (Nov 18, 2010)

Summary

Key Highlights

Frequently Asked Questions